摘要
心率是心血管疾病的重要危险因素,Ⅰ_f抑制剂是一种特异性降低心率的药物。文章综述了Ⅰ_f抑制剂的作用机制与特点以及Ⅱ_f抑制剂在冠心病、心力衰竭等心血管疾病中的应用。
出处
《国外医学（内科学分册）》
2006年第8期323-325,共3页
Foreign Medical Sciences(Section of Internal Medicine)
参考文献21
-
1Dyer AR, Persky V, Stamler J, et al. [J].Am J Epidemiol, 1980,112:736-749.
-
2Kannel WB, Kannel C, Paffenbarger RS, et al.[J]. Am Heart J, 1987,113:1489-1494.
-
3Gillum RF, Makuc DM, Feldman JJ. [J]. Am Heart J, 1991, 121:172-177.
-
4Hjalmarson A, Gilpin EA, Kjekshus J, et al. [J].Am J Cardiol, 1990, 65:547-553.
-
5Lechat P, Hulot JS, Escolano S, et al. [J]. Circulation, 2001,103 : 1428-1433.
-
6Brown HF, DiFrancesco D, Noble SJ. [J].Nature, 1979,280:235-236.
-
7Monnet X, Ghaleh B, Colin P, et al. [J]. J Pharmacol Exp Ther, 2001,299 : 1133-1139.
-
8Borer JS, Fox K, Jaillon P, et al. [J]. Circulation, 2003,107:817-823.
-
9Camm AJ, Lau CP. [J]. Drugs R D, 2003,4:83-89.
-
10Tardif JC, Ford I, Tendera M, et al. [J]. Eur Heart J, 2005,26:2529-2536.
同被引文献16
-
1高照,李法琦.伊伐布雷定减慢心率的研究现状[J].心血管病学进展,2009,30(6):995-998. 被引量：11
-
2梁可,张浩,曹蕾,朱尔佳,谭载友.第一个窦房结I_f电流选择特异性抑制剂——盐酸伊伐布雷定的研究进展[J].中国处方药,2007,6(9):18-19. 被引量：7
-
3TARDIF JC. Ivabradine in clinical practice:benefits of If inhibi- tion[J]. Eur Heart J, 2005, (Suppl H) : H29 -H32.
-
4SORBERA LA, CASTANER J. Ivabradine hydrochloride [ J]. Drugs Fut, 2003,28(7): 652-658.
-
5ECKL KM, THOMSEN T, MOLLER M, et al. The bradycardic effect of the sinoatrial modulator S16257 [ J]. Eur Heart J, 1997, 18(SuaD1) abstract 1047.
-
6FOX K, FERRARI R, TENDERA M, et al. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabra- dine in patients with stable coronary artery disease and left ven- tricular systolic dysfunction:the morbidity-mortality evaluation of the If inhibitor ivabradine in patients with coronary disease and left ventricular dysfunction (BEAUTIFUL) study[ J]. Am Heart J, 2006, 152(5) :860 -866.
-
7FOX K, FORD I, STEG PG,et al. Ivabradine for patients with sta- ble coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL) : a randomised, double-blind, placebo controlled trial[ J]. Lancet,2008,372 (9641) :807 - 816.
-
8RAGUENEAU I, LAVEILLE C, JOCHEMSEN R, et al. Phar- macokinetic-pharmaeodynamie modeling of the effects of ivabra- dine, a direct sinus node inhibitor, on heart rate in healthy vol- unteers[J]. Clin Pharmacol Ther, 1998,64(2) : 192 -203.
-
9DUFFULL SB, AARONS L. Development of a sequential linked pharmacokinetic and pharmacodynamic simulation model for iv- abradine in healthy volunteers[ J] Eur J Pharm Sci, 2000, 10 (4) : 275 -284.
-
10DUFFULL SB, CHABAUD S, NONY P, et al. A pharmacoki- netic simulation model for ivabradine in healthy volunteers [ J ]. Eur J Pharm Sci, 2000, 10(4) : 285 -294.
引证文献2
-
1许莉,蒋娟娟,谢爽,娄莹,王莉,庞会敏,田蕾,李一石.中国健康男性受试者单次口服盐酸伊伐布雷定前后心率与血药浓度的变化[J].中国新药杂志,2013,22(15):1789-1792. 被引量：4
-
2沈阳,马婷伟,吴晶,柴雨柱.正相色谱法测定盐酸伊伐布雷定中对映异构体[J].安徽化工,2023,49(5):138-141.
二级引证文献4
-
1黄龙祥,罗素新.伊伐布雷定在心血管疾病应用中的研究进展[J].心血管病学进展,2014,35(3):375-379. 被引量：17
-
2于怡卉,李明慧,许周涛,胡作英.伊伐布雷定在心血管疾病中的研究新进展[J].中华临床医师杂志（电子版）,2014,8(14):139-142. 被引量：18
-
3侯鹏高,吕长淮.伊伐布雷定药理机制研究概述[J].齐齐哈尔医学院学报,2015,36(20):3071-3072. 被引量：5
-
4董丽春,贺建昌,冯恩富,刘苗,李文锋,龚媛媛,余崇静,吕安安,李星仪,杜鹏,徐贵丽.餐时给药条件下盐酸伊伐布雷定片在健康人体的药动-药效学研究[J].中国临床药理学与治疗学,2016,21(6):667-672.
